<h4>Aims</h4>Chronic kidney disease (CKD) is a common and serious complication of type 2 diabetes, yet the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in non-obese or mildly overweight individuals remains uncertain. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.